Lihat Juga

• Figure 2 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Figure 3 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Figure 1 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Figure 3 from: Kotvitska A, Prokopenko O (2020) Determination of social and economic accessibility of drugs for treatment of Parkinson's disease on the basis of modern approaches. Pharmacia 67(4): 215-221. https://doi.org/10.3897/pharmacia.67.e46586
  oleh: Kotvitska, Alla, et al.
  Terbitan: (2020)